Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Ovarian Neoplasms

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 142 articles:
HTML format



Single Articles


    January 2020
  1. MIAO R, Badger TC, Groesch K, Diaz-Sylvester PL, et al
    Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.
    PLoS One. 2020;15:e0227707.
    PubMed     Abstract available


  2. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    PubMed     Abstract available


  3. AYYAGARI VN, Wang X, Diaz-Sylvester PL, Groesch K, et al
    Assessment of acyl-CoA cholesterol acyltransferase (ACAT-1) role in ovarian cancer progression-An in vitro study.
    PLoS One. 2020;15:e0228024.
    PubMed     Abstract available


  4. ARCHER S, Babb de Villiers C, Scheibl F, Carver T, et al
    Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study.
    PLoS One. 2020;15:e0229999.
    PubMed     Abstract available


  5. WEN H, Qian M, He J, Li M, et al
    Inhibiting of self-renewal, migration and invasion of ovarian cancer stem cells by blocking TGF-beta pathway.
    PLoS One. 2020;15:e0230230.
    PubMed     Abstract available


  6. WU W, Yu LH, Ma B, Xu MJ, et al
    Retraction: The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer.
    PLoS One. 2020;15:e0231890.
    PubMed    


  7. LUBORSKY J, Barua A, Edassery S, Bahr JM, et al
    Inflammasome expression is higher in ovarian tumors than in normal ovary.
    PLoS One. 2020;15:e0227081.
    PubMed     Abstract available


  8. CHAMBERS LM, Esakov E, Braley C, AlHilli M, et al
    Use of Transabdominal Ultrasound for the detection of intra-peritoneal tumor engraftment and growth in mouse xenografts of epithelial ovarian cancer.
    PLoS One. 2020;15:e0228511.
    PubMed     Abstract available


  9. KIM KK, Turner R, Khazan N, Kodza A, et al
    Role of trypsin and protease-activated receptor-2 in ovarian cancer.
    PLoS One. 2020;15:e0232253.
    PubMed     Abstract available


  10. ZENG Y, Chen M, Ganesh S, Hu S, et al
    Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer.
    PLoS One. 2020;15:e0232235.
    PubMed     Abstract available


  11. PRICE JC, Azizi E, Naiche LA, Parvani JG, et al
    Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
    PLoS One. 2020;15:e0233962.
    PubMed     Abstract available


  12. OSTMEYER J, Lucas E, Christley S, Lea J, et al
    Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma.
    PLoS One. 2020;15:e0229569.
    PubMed     Abstract available


  13. ANTON C, Kleine RT, Mayerhoff E, Diz MDPE, et al
    Ten years of experience with endometrial cancer treatment in a single Brazilian institution: Patient characteristics and outcomes.
    PLoS One. 2020;15:e0229543.
    PubMed     Abstract available


  14. HAILU HE, Mondul AM, Rozek LS, Geleta T, et al
    Descriptive Epidemiology of breast and gynecological cancers among patients attending Saint Paul's Hospital Millennium Medical College, Ethiopia.
    PLoS One. 2020;15:e0230625.
    PubMed     Abstract available


  15. SOLDI R, Ghosh Halder T, Weston A, Thode T, et al
    The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    PLoS One. 2020;15:e0235705.
    PubMed     Abstract available


  16. PYEON SY, Han GH, Ki KD, Lee KB, et al
    Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer.
    PLoS One. 2020;15:e0236244.
    PubMed     Abstract available


  17. KELM NQ, Straughn AR, Kakar SS
    Withaferin A attenuates ovarian cancer-induced cardiac cachexia.
    PLoS One. 2020;15:e0236680.
    PubMed     Abstract available


  18. JOHNSON SC, Chakraborty S, Drosou A, Cunnea P, et al
    Inflammatory state of lymphatic vessels and miRNA profiles associated with relapse in ovarian cancer patients.
    PLoS One. 2020;15:e0230092.
    PubMed     Abstract available


    January 2019
  19. HEINZEL A, Marhold M, Mayer P, Schwarz M, et al
    Synthetic lethality guiding selection of drug combinations in ovarian cancer.
    PLoS One. 2019;14:e0210859.
    PubMed     Abstract available


  20. GONG W, Liu Y, Seidl C, Dreyer T, et al
    Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
    PLoS One. 2019;14:e0212968.
    PubMed     Abstract available


  21. NIU L, Li S, Liang H, Li H, et al
    Correction: The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.
    PLoS One. 2019;14:e0218032.
    PubMed     Abstract available


  22. FURRER D, Gregoire J, Turcotte S, Plante M, et al
    Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
    PLoS One. 2019;14:e0218621.
    PubMed     Abstract available


  23. LINDGREN A, Anttila M, Rautiainen S, Arponen O, et al
    Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1alpha expression.
    PLoS One. 2019;14:e0221340.
    PubMed     Abstract available


  24. WICZLING P, Daghir-Wojtkowiak E, Kaliszan R, Markuszewski MJ, et al
    Bayesian multilevel model of micro RNA levels in ovarian-cancer and healthy subjects.
    PLoS One. 2019;14:e0221764.
    PubMed     Abstract available


  25. LIETZ AP, Weaver DT, Melamed A, Rauh-Hain JA, et al
    Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model.
    PLoS One. 2019;14:e0222828.
    PubMed     Abstract available


  26. FRAGOSO-ONTIVEROS V, Velazquez-Aragon JA, Nunez-Martinez PM, de la Luz Mejia-Aguayo M, et al
    Mexican BRCA1 founder mutation: Shortening the gap in genetic assessment for hereditary breast and ovarian cancer patients.
    PLoS One. 2019;14:e0222709.
    PubMed     Abstract available


  27. GORZELITZ J, Costanzo ES, Spencer RJ, Rumble M, et al
    Longitudinal assessment of post-surgical physical activity in endometrial and ovarian cancer patients.
    PLoS One. 2019;14:e0223791.
    PubMed     Abstract available


  28. AMIT A, Sabo E, Movsas A, Efrat-Tamam Y, et al
    Can morphometric analysis of the fallopian tube fimbria predict the presence of uterine papillary serous carcinoma (UPSC)?
    PLoS One. 2019;14:e0211329.
    PubMed     Abstract available


  29. DURAN GE, Sikic BI
    The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
    PLoS One. 2019;14:e0210879.
    PubMed     Abstract available


  30. MRKVICOVA A, Chmelarova M, Peterova E, Havelek R, et al
    The effect of sodium butyrate and cisplatin on expression of EMT markers.
    PLoS One. 2019;14:e0210889.
    PubMed     Abstract available


  31. TORRES D, Hou X, Bale L, Heinzen EP, et al
    Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    PLoS One. 2019;14:e0224564.
    PubMed     Abstract available


  32. OLIVEIRA DNP, Carlsen AL, Heegaard NHH, Prahm KP, et al
    Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
    PLoS One. 2019;14:e0225249.
    PubMed     Abstract available


  33. WANG F, Chen X, Yuan D, Yi Y, et al
    Golgi reassembly and stacking protein 65 downregulation is required for the anti-cancer effect of dihydromyricetin on human ovarian cancer cells.
    PLoS One. 2019;14:e0225450.
    PubMed     Abstract available


  34. WAMBECKE A, Laurent-Issartel C, Leroy-Dudal J, Giffard F, et al
    Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.
    PLoS One. 2019;14:e0225860.
    PubMed     Abstract available


  35. ZHAO Y, Mehta M, Walton A, Talsania K, et al
    Robustness of RNA sequencing on older formalin-fixed paraffin-embedded tissue from high-grade ovarian serous adenocarcinomas.
    PLoS One. 2019;14:e0216050.
    PubMed     Abstract available


  36. CHE L, Yang X, Ge C, El-Amouri SS, et al
    Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.
    PLoS One. 2019;14:e0216553.
    PubMed     Abstract available


  37. MARTINEZ-MAS J, Bueno-Crespo A, Khazendar S, Remezal-Solano M, et al
    Evaluation of machine learning methods with Fourier Transform features for classifying ovarian tumors based on ultrasound images.
    PLoS One. 2019;14:e0219388.
    PubMed     Abstract available


  38. KIM B, Won D, Lee ST, Choi JR, et al
    Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
    PLoS One. 2019;14:e0217521.
    PubMed     Abstract available


  39. ZEH N, Schneider H, Mathias S, Raab N, et al
    Human CAP cells represent a novel source for functional, miRNA-loaded exosome production.
    PLoS One. 2019;14:e0221679.
    PubMed     Abstract available


  40. BISHOP MR, Huskey ALW, Hetzel J, Merner ND, et al
    A research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.
    PLoS One. 2019;14:e0220929.
    PubMed     Abstract available


  41. ANDRADE DAP, da Silva VD, Matsushita GM, de Lima MA, et al
    Squamous differentiation portends poor prognosis in low and intermediate-risk endometrioid endometrial cancer.
    PLoS One. 2019;14:e0220086.
    PubMed     Abstract available


    January 2018
  42. SHAHZAD MMK, Felder M, Ludwig K, Van Galder HR, et al
    Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src.
    PLoS One. 2018;13:e0189524.
    PubMed     Abstract available


  43. WANG KH, Wang YM, Chiu LH, Chen TC, et al
    Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.
    PLoS One. 2018;13:e0192047.
    PubMed     Abstract available


  44. LUO H, Xu X, Ye M, Sheng B, et al
    The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.
    PLoS One. 2018;13:e0191972.
    PubMed     Abstract available


  45. ZHANG R, Pu W, Zhang S, Chen L, et al
    Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial.
    PLoS One. 2018;13:e0191756.
    PubMed     Abstract available


  46. SINGH G, Roy J, Rout P, Mallick B, et al
    Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers.
    PLoS One. 2018;13:e0190485.
    PubMed     Abstract available


  47. HOU S, Dai J
    Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer.
    PLoS One. 2018;13:e0192812.
    PubMed     Abstract available


  48. HYLER AR, Baudoin NC, Brown MS, Stremler MA, et al
    Fluid shear stress impacts ovarian cancer cell viability, subcellular organization, and promotes genomic instability.
    PLoS One. 2018;13:e0194170.
    PubMed     Abstract available


  49. NOEL-MACDONNELL JR, Usset J, Goode EL, Fridley BL, et al
    Assessment of data transformations for model-based clustering of RNA-Seq data.
    PLoS One. 2018;13:e0191758.
    PubMed     Abstract available


  50. CHUDECKA-GLAZ A, Cymbaluk-Ploska A, Wezowska M, Menkiszak J, et al
    Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
    PLoS One. 2018;13:e0194270.
    PubMed     Abstract available


  51. CHANG LC, Huang CF, Lai MS, Shen LJ, et al
    Prognostic factors in epithelial ovarian cancer: A population-based study.
    PLoS One. 2018;13:e0194993.
    PubMed     Abstract available


  52. NEYT M, Vlayen J, Devriese S, Camberlin C, et al
    First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
    PLoS One. 2018;13:e0195134.
    PubMed     Abstract available


  53. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeillinger R, et al
    Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2018;13:e0196142.
    PubMed     Abstract available


  54. ZHANG T, Xu J, Deng S, Zhou F, et al
    Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data.
    PLoS One. 2018;13:e0196351.
    PubMed     Abstract available


  55. AITHAL A, Junker WM, Kshirsagar P, Das S, et al
    Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    PLoS One. 2018;13:e0193907.
    PubMed     Abstract available


  56. ALEMAR B, Gregorio C, Herzog J, Matzenbacher Bittar C, et al
    Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    PLoS One. 2018;13:e0197529.
    PubMed     Abstract available


  57. HECKL M, Schmoeckel E, Hertlein L, Rottmann M, et al
    The ARID1A, p53 and ss-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    PLoS One. 2018;13:e0192881.
    PubMed     Abstract available


  58. HE X, Yang K, Wang H, Chen X, et al
    Expression and clinical significance of survivin in ovarian cancer: A meta-analysis.
    PLoS One. 2018;13:e0194463.
    PubMed     Abstract available


  59. CAI Q, Fan Q, Buechlein A, Miller D, et al
    Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells.
    PLoS One. 2018;13:e0197404.
    PubMed     Abstract available


  60. TEA MM, Tan YY, Staudigl C, Eibl B, et al
    Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool.
    PLoS One. 2018;13:e0200559.
    PubMed     Abstract available


  61. EARP M, Tyrer JP, Winham SJ, Lin HY, et al
    Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility.
    PLoS One. 2018;13:e0197561.
    PubMed     Abstract available


  62. YEH CC, Su FH, Tzeng CR, Muo CH, et al
    Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study.
    PLoS One. 2018;13:e0194011.
    PubMed     Abstract available


  63. MITCHELL R, Buckingham L, Cobleigh M, Rotmensch J, et al
    Can chimerism explain breast/ovarian cancers in BRCA non-carriers from BRCA-positive families?
    PLoS One. 2018;13:e0195497.
    PubMed     Abstract available


  64. RHYASEN GW, Yao Y, Zhang J, Dulak A, et al
    BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
    PLoS One. 2018;13:e0200826.
    PubMed     Abstract available


  65. MONTAVON SARTORIUS C, Schoetzau A, Kettelhack H, Fink D, et al
    ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.
    PLoS One. 2018;13:e0195213.
    PubMed     Abstract available


  66. JANSEN RJ, Alexander BH, Hayes RB, Miller AB, et al
    A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
    PLoS One. 2018;13:e0194608.
    PubMed     Abstract available


  67. WANG KH, Wang YM, Chiu LH, Chen TC, et al
    Correction: Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.
    PLoS One. 2018;13:e0202610.
    PubMed     Abstract available


  68. LEE YJ, Lee IH, Kim YJ, Chung YS, et al
    Evaluation of various kinetic parameters of CA-125 in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    PLoS One. 2018;13:e0203366.
    PubMed     Abstract available


  69. ZHENG G, Yu H, Kanerva A, Forsti A, et al
    Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    PLoS One. 2018;13:e0205000.
    PubMed     Abstract available


  70. FUJISAWA M, Moh-Moh-Aung A, Zeng Z, Yoshimura T, et al
    Ovarian stromal cells as a source of cancer-associated fibroblasts in human epithelial ovarian cancer: A histopathological study.
    PLoS One. 2018;13:e0205494.
    PubMed     Abstract available


  71. ZHENG G, Yu H, Kanerva A, Forsti A, et al
    Correction: Familial risks of ovarian cancer by age at diagnosis, proband type and histology.
    PLoS One. 2018;13:e0206721.
    PubMed     Abstract available


  72. SHIH AJ, Menzin A, Whyte J, Lovecchio J, et al
    Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.
    PLoS One. 2018;13:e0206785.
    PubMed     Abstract available


  73. STARBUCK KD, Szender JB, Duncan WD, Morrell K, et al
    Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer.
    PLoS One. 2018;13:e0206913.
    PubMed     Abstract available


  74. LIN ZP, Zhu YL, Lo YC, Moscarelli J, et al
    Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    PLoS One. 2018;13:e0207399.
    PubMed     Abstract available


  75. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer.
    PLoS One. 2018;13:e0207319.
    PubMed     Abstract available


  76. SHIH AJ, Menzin A, Whyte J, Lovecchio J, et al
    Correction: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.
    PLoS One. 2018;13:e0208778.
    PubMed     Abstract available


  77. YODSURANG V, Tang Y, Takahashi Y, Tanikawa C, et al
    Genome-wide association study (GWAS) of ovarian cancer in Japanese predicted regulatory variants in 22q13.1.
    PLoS One. 2018;13:e0209096.
    PubMed     Abstract available


  78. DEDOVA T, Grunow D, Kappert K, Flach D, et al
    The effect of blood sampling and preanalytical processing on human N-glycome.
    PLoS One. 2018;13:e0200507.
    PubMed     Abstract available


  79. EAVARONE DA, Al-Alem L, Lugovskoy A, Prendergast JM, et al
    Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.
    PLoS One. 2018;13:e0201314.
    PubMed     Abstract available


  80. NAGORSKI J, Allen GI
    Genomic region detection via Spatial Convex Clustering.
    PLoS One. 2018;13:e0203007.
    PubMed     Abstract available


    January 2017
  81. FAKKERT IE, van der Veer E, Abma EM, Lefrandt JD, et al
    Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.
    PLoS One. 2017;12:e0169673.
    PubMed     Abstract available


  82. SEEBACHER V, Reinthaller A, Koelbl H, Concin N, et al
    The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.
    PLoS One. 2017;12:e0169272.
    PubMed     Abstract available


  83. LEE HH, Bellat V, Law B
    Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer.
    PLoS One. 2017;12:e0171044.
    PubMed     Abstract available


  84. BAI L, Wang H, Wang AH, Zhang LY, et al
    MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.
    PLoS One. 2017;12:e0173912.
    PubMed     Abstract available


  85. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
    PLoS One. 2017;12:e0174300.
    PubMed     Abstract available


  86. MA Z, Wang X, He J, Xia J, et al
    Increased expression of protein kinase CK2alpha correlates with poor patient prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0174037.
    PubMed     Abstract available


  87. COZZI GD, Levinson RT, Toole H, Snyder MR, et al
    Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0175119.
    PubMed     Abstract available


  88. BRENCICOVA E, Jagger AL, Evans HG, Georgouli M, et al
    Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
    PLoS One. 2017;12:e0175712.
    PubMed     Abstract available


  89. GRAUMANN R, Di Capua GA, Oyarzun JE, Vasquez MA, et al
    Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.
    PLoS One. 2017;12:e0177244.
    PubMed     Abstract available


  90. CHEN WC, Qiu JT, Lai CH, Huang HJ, et al
    Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
    PLoS One. 2017;12:e0175703.
    PubMed     Abstract available


  91. LIU C, Zhang Y, Jiang H, Wu H, et al
    Association between social support and post-traumatic stress disorder symptoms among Chinese patients with ovarian cancer: A multiple mediation model.
    PLoS One. 2017;12:e0177055.
    PubMed     Abstract available



  92. Correction: Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0178965.
    PubMed     Abstract available


  93. STAFFORD JL, Dyson G, Levin NK, Chaudhry S, et al
    Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
    PLoS One. 2017;12:e0178450.
    PubMed     Abstract available


  94. ZHANG W, Su J, Xu H, Yu S, et al
    Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    PLoS One. 2017;12:e0179672.
    PubMed     Abstract available


  95. BJERSAND K, Seidal T, Sundstrom-Poromaa I, Akerud H, et al
    The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0179363.
    PubMed     Abstract available


  96. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2017;12:e0179501.
    PubMed     Abstract available


  97. WAN X, Bovornchutichai P, Cui Z, O'Neill E, et al
    Morphological analysis of human umbilical vein endothelial cells co-cultured with ovarian cancer cells in 3D: An oncogenic angiogenesis assay.
    PLoS One. 2017;12:e0180296.
    PubMed     Abstract available


  98. CHAO TK, Huang TS, Liao YP, Huang RL, et al
    Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    PLoS One. 2017;12:e0182166.
    PubMed     Abstract available


  99. LANDSKRON J, Kraggerud SM, Wik E, Dorum A, et al
    C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
    PLoS One. 2017;12:e0182030.
    PubMed     Abstract available


  100. PAULLIN T, Powell C, Menzie C, Hill R, et al
    Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses.
    PLoS One. 2017;12:e0182930.
    PubMed     Abstract available


  101. ROZENBLUM E, Sotelo-Silveira JR, Kim GY, Zhu JY, et al
    Novel near-diploid ovarian cancer cell line derived from a highly aneuploid metastatic ovarian tumor.
    PLoS One. 2017;12:e0182610.
    PubMed     Abstract available


  102. PETERS IT, van Zwet EW, Smit VT, Liefers GJ, et al
    Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.
    PLoS One. 2017;12:e0168277.
    PubMed     Abstract available


  103. ZHU J, Wen H, Ju X, Bi R, et al
    Clinical Significance of Programmed Death Ligand1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
    PLoS One. 2017;12:e0170879.
    PubMed     Abstract available


  104. SEEBACHER V, Aust S, D'Andrea D, Grimm C, et al
    Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.
    PLoS One. 2017;12:e0182383.
    PubMed     Abstract available


  105. HAIMOVICH JS, Venkatesh AK, Shojaee A, Coppi A, et al
    Discovery of temporal and disease association patterns in condition-specific hospital utilization rates.
    PLoS One. 2017;12:e0172049.
    PubMed     Abstract available


  106. JIA ZH, Jia Y, Guo FJ, Chen J, et al
    Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer.
    PLoS One. 2017;12:e0183622.
    PubMed     Abstract available


  107. CHUNG YS, Kim YJ, Lee I, Lee JY, et al
    Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
    PLoS One. 2017;12:e0183754.
    PubMed     Abstract available


  108. ZHANG H, Lu J, Lu Y, Zhou J, et al
    Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma.
    PLoS One. 2017;12:e0177520.
    PubMed     Abstract available


  109. ROSSO M, Majem B, Devis L, Lapyckyj L, et al
    E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.
    PLoS One. 2017;12:e0184439.
    PubMed     Abstract available


  110. AYYAGARI VN, Diaz-Sylvester PL, Hsieh TJ, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
    PLoS One. 2017;12:e0185111.
    PubMed     Abstract available


  111. GRANATA V, Fusco R, Catalano O, Avallone A, et al
    Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.
    PLoS One. 2017;12:e0179951.
    PubMed     Abstract available


  112. YANAGIDA S, Anglesio MS, Nazeran TM, Lum A, et al
    Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.
    PLoS One. 2017;12:e0178989.
    PubMed     Abstract available


  113. LIN KT, Sun SP, Wu JI, Wang LH, et al
    Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.
    PLoS One. 2017;12:e0178937.
    PubMed     Abstract available


  114. SUNG PL, Wen KC, Chen YJ, Chao TC, et al
    The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    PLoS One. 2017;12:e0185615.
    PubMed     Abstract available


  115. ZHU XM, Sun WF
    Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review.
    PLoS One. 2017;12:e0185456.
    PubMed     Abstract available


  116. TAO X, Chen L, Ge S, Cai L, et al
    Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: A meta-analysis.
    PLoS One. 2017;12:e0177426.
    PubMed     Abstract available


  117. HARTER P, Hauke J, Heitz F, Reuss A, et al
    Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    PLoS One. 2017;12:e0186043.
    PubMed     Abstract available


  118. GUO Z, Wang X, Cheng D, Xia Z, et al
    Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.
    PLoS One. 2017;12:e0186965.
    PubMed     Abstract available


  119. VALIANATOS G, Valcikova B, Growkova K, Verlande A, et al
    A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.
    PLoS One. 2017;12:e0185801.
    PubMed     Abstract available


  120. FORNARO L, Vivaldi C, Lin D, Xue H, et al
    Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation.
    PLoS One. 2017;12:e0182818.
    PubMed     Abstract available


  121. YANG L, Zhang B, Xing G, Du J, et al
    Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2017;12:e0186725.
    PubMed     Abstract available


  122. GENG X, Liu Y, Diersch S, Kotzsch M, et al
    Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.
    PLoS One. 2017;12:e0186847.
    PubMed     Abstract available


  123. QIN L, Li T, Liu Y
    High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer.
    PLoS One. 2017;12:e0187385.
    PubMed     Abstract available


  124. CHESNAIS M, Lecuru F, Mimouni M, Ngo C, et al
    A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
    PLoS One. 2017;12:e0187245.
    PubMed     Abstract available


  125. ALEMAR B, Gregorio C, Herzog J, Matzenbacher Bittar C, et al
    BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    PLoS One. 2017;12:e0187630.
    PubMed     Abstract available


  126. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeilinger R, et al
    Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2017;12:e0189641.
    PubMed     Abstract available


  127. KUROKI LM, Jin X, Dmitriev IP, Kashentseva EA, et al
    Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.
    PLoS One. 2017;12:e0190125.
    PubMed     Abstract available


  128. COUTTENIER A, Lacroix O, Vaes E, Cardwell CR, et al
    Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study.
    PLoS One. 2017;12:e0189233.
    PubMed     Abstract available


  129. OBATA T, Nakamura M, Mizumoto Y, Iizuka T, et al
    Dual expression of immunoreactive estrogen receptor beta and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
    PLoS One. 2017;12:e0188641.
    PubMed     Abstract available


  130. JIN D, Lee H
    FGMD: A novel approach for functional gene module detection in cancer.
    PLoS One. 2017;12:e0188900.
    PubMed     Abstract available


  131. CHEN Y, Bieber MM, Bhat NM, Teng NNH, et al
    Ovarian carcinoma glyco-antigen targeted by human IgM antibody.
    PLoS One. 2017;12:e0187222.
    PubMed     Abstract available


    January 2016
  132. TUMBARELLO DA, Andrews MR, Brenton JD
    SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
    PLoS One. 2016;11:e0162698.
    PubMed     Abstract available


  133. XIAO X, Cai F, Niu X, Shi H, et al
    Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies.
    PLoS One. 2016;11:e0163257.
    PubMed     Abstract available


  134. LI L, Luo Q, Xie Z, Li G, et al
    Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer.
    PLoS One. 2016;11:e0163447.
    PubMed     Abstract available


  135. IGNACIO RM, Kabir SM, Lee ES, Adunyah SE, et al
    NF-kappaB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
    PLoS One. 2016;11:e0164189.
    PubMed     Abstract available


  136. POCHECHUEVA T, Chinarev A, Schoetzau A, Fedier A, et al
    Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
    PLoS One. 2016;11:e0164230.
    PubMed     Abstract available


  137. FEDOSEIENKO A, Wieringa HW, Wisman GB, Duiker E, et al
    Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
    PLoS One. 2016;11:e0165385.
    PubMed     Abstract available


  138. SUN S, Cai J, Yang Q, Zhu Y, et al
    Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0166058.
    PubMed     Abstract available


  139. PENNINGTON M, Gentry-Maharaj A, Karpinskyj C, Miners A, et al
    Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    PLoS One. 2016;11:e0165539.
    PubMed     Abstract available


  140. RASOOL M, Malik A, Basit Ashraf MA, Parveen G, et al
    Evaluation of Matrix Metalloproteinases, Cytokines and Their Potential Role in the Development of Ovarian Cancer.
    PLoS One. 2016;11:e0167149.
    PubMed     Abstract available


  141. POWELL CD, Paullin TR, Aoisa C, Menzie CJ, et al
    The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.
    PLoS One. 2016;11:e0168389.
    PubMed     Abstract available


  142. TAO F, Ruan S, Liu W, Wang L, et al
    Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2016;11:e0168892.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: